Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02163824 · ClinicalTrials.gov registry record · Phase 3
Safety and Efficacy of KPI-121 in Subjects With Postsurgical Inflammation
A Phase 3 study, sponsored by Kala Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 380
- Enrollment target
NCT02163824 is a Phase 3 study that has completed, run by Kala Pharmaceuticals. The registered enrollment target is 380 participants.
The verdict
NCT02163824, a Phase 3 study, has completed, sponsored by Kala Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 380 participants
- Enrollment target
Study Summary
The primary purpose of this study is to determine the efficacy and safety of KPI-121 ophthalmic suspension compared to placebo in subjects who have undergone cataract surgery. The efficacy and safety of two different concentrations and two different dosing regimens of KPI-121 are also being assessed.
Interventions
- DRUG KPI-121 0.25%
- DRUG KPI-121 1.0%
- DRUG Vehicle of KPI-121 0.25%
- DRUG Vehicle of KPI-121 1.0%
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 380 participants |
| Start Date | 2014-05 |
| Est. Completion | 2014-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02163824
The ClinicalTrials.gov registry entry for NCT02163824 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 380 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Kala Pharmaceuticals, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which KPI-121 0.25% is the first listed.
NCT02163824 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02163824 about?
NCT02163824 is a clinical study titled "Safety and Efficacy of KPI-121 in Subjects With Postsurgical Inflammation". The primary purpose of this study is to determine the efficacy and safety of KPI-121 ophthalmic suspension compared to placebo in subjects who have undergone cataract surgery. The efficacy and safety of two different concentrations and two different dosing regimens of KPI-121 are also being assessed...
What is the current status of trial NCT02163824?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 380 participants. The study started on 2014-05. Estimated completion is 2014-12.
What interventions are being tested in trial NCT02163824?
The interventions under investigation include: KPI-121 0.25% (DRUG), KPI-121 1.0% (DRUG), Vehicle of KPI-121 0.25% (DRUG), Vehicle of KPI-121 1.0% (DRUG).
Who is sponsoring clinical trial NCT02163824?
This trial is sponsored by Kala Pharmaceuticals, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.